← Back to patent-cliff list
rineterkib
Tier C — Watch / traderineterkib
Novartis
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：ERK1, ERK2
Indications (approved)：Melanoma, Myelofibrosis, Colorectal cancer, Non-small cell lung cancer, Ovarian cancer, Solid tumour
Regional status
US
Phase II
2020-10-30
EU
Phase II
2020-10-30
China
Phase I
2022-03-01
Japan
Discontinued
2016-04-15
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of rineterkib?
Approved indications include: Melanoma, Myelofibrosis, Colorectal cancer, Non-small cell lung cancer, Ovarian cancer, Solid tumour.
When does the rineterkib patent expire?
No public expiry year is available for rineterkib yet; this page updates once verified.
How do I get a quote for rineterkib intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-06